Tech Company Inital Public Offerings
Entrada Therapeutics IPO
Entrada Therapeutics was bought by . Entrada Therapeutics shares started trading on 10/29/2021.
Transaction Overview
Company Name
Announced On
10/29/2021
Transaction Type
IPO
Amount
$181,500,000
Proceeds Purpose
We intend to use the net proceeds from this offering to fund the development of ENTR-601-44 into clinical development through our planned single ascending dose clinical trial in healthy volunteers; to fund the continued development of our DM1 program, including the selection of a EEV therapeutic candidate through IND submission; to fund the advancement of our development portfolio toward selection of an EEV therapeutic candidate in each of immunology, oncology and neurodegenerative disease; for the continued development and enhancement of our EEV platform; and for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6 Tide St.
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Entrada Therapeutics' mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada's technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dipal Doshi
Chief Financial Officer
Kory Wentworth
Chief Medical Officer
Nerissa Kreher
Chief Operating Officer
Nathan Dowden
Chief Scientific Officer
Natarajan Sethuraman
VP - General Counsel
Jared Cohen
VP - Human Resources
Kerry Robert
Browse more venture capital transactions:
Prev: 10/29/2021: Needed venture capital transaction
Next: 10/29/2021: Ontra venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs